Limitations: - CT-388 data is early stage (Phase 1/2), making comparisons to late-stage or approved competitors regarding efficacy somewhat premature.- Competitor trials involving semaglutide and tirzepatide are based on larger patient populations and longer duration, providing a more robust data set validating their therapeutic benefit.- Weight loss achieved with GLP-1 receptor agonists such as semaglutide and the dual GLP-1/GIP receptor agonist tirzepatide appear greater than the weight loss observed to date with CT-388.- Competitor agents have established cardiovascular benefits and substantial net weight reductions, which set a high efficacy bar for CT-388 to meet or exceed.- Incretin therapies are challenged by supply shortages and complex titration schemes
If you have Pernicious Aneamia then it is possible you have other autoimmune conditions, for instance Hashimotos (where the immune system attacks the thyroid), type 1 diabetes, Sjogrens Syndrome etc
They may be sort of in that state for months where they're moving much
The goal is to find the lowest effective dose of each medication to achieve the desired improvement in sexual function while keeping side effects to a minimum
I think Gutin may have been drawn to booths that had extra room for him to squeeze in
plan changes require active contact with the care team and don't happen automatically
